A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Eli Lilly and Company
Hoffmann-La Roche
M.D. Anderson Cancer Center
AstraZeneca
Seagen Inc.
University of Kansas Medical Center
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Johns Hopkins University